Member Info for oogleflugal

Some thumping trades this morning. Two well over a million and two at half a million. I was wondering about the surplus cash. Ip dividend is not overly generous. Singer say there remains the opportunity for second special dividend on top of the maiden dividend. Be nice if they could manage both and the takeover!

SB. Indeed the hidden asset of 600 million tax credit as Chris Mills put it. Plus 22.5 million cash as of end of february. Valuation doesnt look stretched to me for 18 % growth compounding. The market is also growing possibly to 400 million in next decade. The improvement and cost of drugs also necessitates the accuracy of Feno for which Niox are currently in a field of their own.

Confirmed 23 year results from January. 18 percent revenue growth. 1p dividend confirmed for 2023 but no date set yet. Nearly 20 million cash balance plus whatever assets year (possibly another 5 million) . Lungfit approval in USA to add 10 million dollars over 3 years. Strong point made about the importance of the uptake of FeNo testing with better and more expensive drugs becoming available. Asset value just over 80 million. All in all the stock set to become very undervalued if progress only continues at this pace but of course likely to accelerate further with development of home kit and the larger updated version of current diagnostic machine. Still early days for a bid maybe, but depends how much quicker a larger company could place and develop their products. I would imagine the current sp would be largely supported by todays update, but who can tell in this mad market!

Apart from results being overdue. The review is over due. The dividend was reinstated in feb payed out a couple of days ago? With an offer to reinvest dividends . Doesn’t sound like a company in trouble it’s the markets in general that are in trouble over reacting to every tiny bit of gossip/news item or no news . I would imagine the outcome of the late review would have some bearing on an update date. As previously mentioned jobsworth stringing it out for a ridiculous length of time while god knows what skullduggery is being perpetrated all over the markets completely un hindered by anything approaching the semblance of a regulator

Thunderbird. Can you name one single financial institution that is squeaky clean? Hsba have been pinged on more than one occasion For money laundering. Let’s not even go down the road of what RBS and bank of Scotland got up to. The Halifax jeez! I can see why it’s taken the USA to ask an extradition order on Mr Lynch’s activities in Autonomy. Where were the uk regulators there? The financial regulators in this country are either blind, stupid, lazy or all three, obviously inadequately funded. I believe that nominee accounts are actually ring fenced, legally segregated from creditors in the event of bankruptcy. I have no wish to test this theory, or the one about an £85000 cash guaranteed. Can you imagine what would happen to companies holding several million in cash? It’s a typical insurance scam like the one about peace of mind. That’s about all you get till you put a claim in, then the nightmare begins! There are no people in finance you can trust, speaking as a former trustee.

Stuartm. Jobsworths. Why pick on Jarvis. Can’t say I have ever had interest paid on cash. That’s why I don’t leave any in the account. They have stopped trades allowed against the value of the portfolio. Again I’ m really not that stupid. Igg don’t pay interest. iWeb (sub of Lloyds) don’t pay interest. The wealth manager I had short chat with didn’t even know they owned iWeb. Barclays don’t pay interest. Pershing securities don’t pay interest. None of them ever have, even when interest rates were much higher. That’s how they achieve lower trading costs. In the old days was like selling a house through an agent with similar fees. If you had a managed account the used to call it share shuffling to make themselves a decent income, never mind if they were loosing you money every time. Never had an issue with Jarvis. Best broker by a country mile. Go chase some real crooks!

Cancel the Panda!

Results ‘as expected.’ Market hates a dividend cut. Business streamlined and new facilities in Cardiff. Missed the meeting but will watch replay. Looks ok to me, was not expecting miracles. Looking forward looks pretty exciting . Will another US company pounce on this derisory price . I know I have. Gl

And Greggs now. Are people putting 2 and 2 together and getting the wrong answer?

Continuing strength in trading. After all this time I think there will be an offer. Maybe not a winning one. Not completely clear about the wisdom of putting it up for sale. Good promotion for business ?

Stable. But need to run a tighter ship. Paying top dollar management fees for slap dash management

Cannicord dropped less than 1 percent 15 to 14. Big deal. Sp off 6 per cent! Sainsbury and Tesco better ask for their services

Indeed Johno. Maybe even trade up to a Panda!

I was just thinking those two trades reported as sells were poorly timed, but they may well have been purchases. It has been hard for holders to keep believing in this, now it looks as if we might really be in the home straight I hope we are not going to be dashed again not least for the sake of cancer patients and people hoping to save their sight. This has been a long journey from a possible vaccine delivery vehicle to enhancing the delivery of cancer treatment more effectively and safely. Gl

Generally trust funds have been abysmal across the board. A small part can be put down to widening nav discount . Some funds are trading at almost 50% discount to nav. Not quite the case here. BG have even performed poorly in America where the Dow has hit record highs.i thought Japan looked good for recovery after the Olympics, and yes currency had also been an issue. I watched a very amateur presentation by the guy who runs BGFD . It was embarrassingly awful. They did a lot of share shuffling a while back which looks to have done further damage to the trust. I had five trusts and decided to ditch the lot including Schroders which actually has performed quite well. Stock picking is more crucial than ever and I feel the problem is that they have too much money to manage. Personally I doubt I would ever buy a trust fund again. Aside from loosing capital value, few even pay a decent dividend, while some of my stocks yield anywhere between 3 and 7%. I had done ok in Japan, sold up and then also thought it was looking cheap. I cut my losses last year and fortunately made up the losses pretty quick. It is a very tricky environment both politically and climate wise. i seem to recall Japan recently escaped another tsunami, but they did have a tremor or two I think. There is always something to worry about. Its either a ten year investment to tuck away and forget or you have to get much more hands on and cut losses . I chose the latter. Gl

Just waited for confirmation on small cap report on renx from Paul Scott. He makes a very good point about the cash burn and possible further raise . On the takeover he asks why would anyone buy Renx when in all liklihood they can buy it out of administration? I saw someone arguing not to wait to see if it drops below placing price and why you should buy at todays price. I cant see that argument stacks up at all. Be interesting to see what Harwood does. So that leaves me with the choice of Vrci or more EKF… or more of the sllightly better Harwood case Niox! think I have overdone that already

I see Ring Central is a 3.3 billion dollar company. This is a partnership rather than a contact. So basically they are saying ECK has access to all their clients. Could be very juicy!

Just been relistening to Chris Mills discussing all three companies with Paul Hill recently. Ekf looks the strongest currently, with Mills on the board and he recently bought 100k shares@30p. He also flagged up that Rnex was running out of cash and needed a dramatic cash injection which unfolded today conveniently after the alleged approach which drove the sp conveniently up to 60p , nice timing . Tempted at this price, but maybe not that desperate to honest in this market! As chris says life science is not the easiest thing to raise cash for at the moment. Vrci on the other hand managed that quite successfully and I did mean to buy into that, but bought more ekf at 27p recently. Results expected to be conservatively in line with growth in the diagnostics side but nothing priced in for the enzyme business which is probably a year away from orders still.

Another fund chucking their clients money down the pan. Seem to be plenty of buyers mopping up.

New contract with Ring Central to add to many other new contracts. Doesn’t say the actual size, but must be pretty decent. I suppose the market will eventually acknowledge the turn around here.